ArticleJournal of cachexia, sarcopenia and muscle2025
Exploration of Fully-Automated Body Composition Analysis Using Routine CT-Staging of Lung Cancer Patients for Survival Prognosis.
Article in Journal of cachexia, sarcopenia and muscle, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- A machine learning-derived sarcopenia index is associated with survival and nonrelapse mortality in DLBCL.Blood advances · 2026Article
- Prediction of Overall Survival in Patients With Oesophageal Cancer Using AI-Based 3D CT Body Composition Analysis.Journal of cachexia, sarcopenia and muscle · 2026Article
- Article
- From Pixels to Prediction: Reviewing the Role of Artificial Intelligence in Body Composition Analysis.Journal of cachexia, sarcopenia and muscle · 2026Review
- AI-Based Imaging Assessment of Body Composition in Oncology: A Step Toward Routine Clinical Practice Integration.Healthcare (Basel, Switzerland) · 2026Article
- Multidimensional modeling and stratification of nutritional risk in non-small cell lung cancer based on artificial intelligence-derived CT body composition phenotypes.Frontiers in nutrition · 2026Article
- Intramuscular Fat as a Biomarker of Muscle Health: Strengths, Limitations and Open Challenges.Journal of cachexia, sarcopenia and muscle · 2026Review
- Exploration of Fully-Automated Body Composition Analysis Using Routine CT-Staging of Lung Cancer Patients for Survival Prognosis.Journal of cachexia, sarcopenia and muscle · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundAI-driven automated body composition analysis (BCA) may provide quantitative prognostic biomarkers derived from routine staging CTs. This two-centre study evaluates the prognostic value of these volumetric markers for overall survival in lung cancer patients.
methodsLung cancer cohorts from Hospital A (n = 3345, median age 65, 86% NSCLC, 40% M1, 40% female) and B (n = 1364, median age 66, 87% NSCLC, 37% M1, 38% female) underwent automated BCA of abdominal CTs ±60 days of primary diagnosis. A deep learning network segmented muscle, bone and adipose tissues (visceral = VAT, subcutaneous = SAT, intra-/intermuscular = IMAT and total = TAT) to derive three markers: Sarcopenia Index (SI = Muscle/Bone), Myosteatotic Fat Index (MFI = IMAT/TAT) and Abdominal Fat Index (AFI = VAT/SAT). Kaplan-Meier survival analysis, Cox proportional hazards modelling and machine learning-based survival prediction were performed. A survival model including clinical data (BMI, ECOG, L3-SMI, -SATI, -VATI and -IMATI) was fitted on Hospital A data and validated on Hospital B data.
resultsIn nonmetastatic NSCLC, high SI predicted longer survival across centres for males (Hospital A: 24.6 vs. 46.0 months; Hospital B: 13.3 vs. 28.9 months; both p < 0.001) and females (Hospital A: 37.9 vs. 53.6 months, p = 0.008; Hospital B: 23.0 vs. 28.6 months, p = 0.018). High MFI indicated reduced survival in males at both hospitals (Hospital A: 43.7 vs. 28.2 months; Hospital B: 28.8 vs. 14.3 months; both p ≤ 0.001) but showed center-dependent effects in females (significant only in Hospital A, p < 0.01). In metastatic disease, SI remained prognostic for males at both centres (p < 0.05), while MFI was significant only in Hospital A (p ≤ 0.001) and AFI only in Hospital B (p = 0.042). Multivariate Cox regression confirmed that higher SI was protective (A: HR 0.53, B: 0.59, p ≤ 0.001), while MFI was associated with shorter survival (A: HR 1.31, B: 1.12, p < 0.01). The multivariate survival model trained on Hospital A's data demonstrated prognostic differentiation of groups in internal (n = 209, p ≤ 0.001) and external (Hospital B, n = 361, p = 0.044) validation, with SI feature importance (0.037) ranking below ECOG (0.082) and M-status (0.078), outperforming all other features including conventional L3-single-slice measurements.
conclusionCT-based volumetric BCA provides prognostic biomarkers in lung cancer with varying significance by sex, disease stage and centre. SI was the strongest prognostic marker, outperforming conventional L3-based measurements, while fat-related markers showed varying associations. Our multivariate model suggests that BCA markers, particularly SI, may enhance risk stratification in lung cancer, pending centre-specific and sex-specific validation. Integration of these markers into clinical workflows could enable personalized care and targeted interventions for high-risk patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.